AYTU Stock Analysis: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$2.34
-0.03 (-1.36%)
âŧ
5d:
-0.94%
30d:
+8.23%
90d:
+6.74%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Sep 22, 2026
28d
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: AYTU is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: AYTU is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $2.34, which is considered slightly high relative to its 30-day fair value range of $2.15 to $2.36. From a valuation perspective, the stock is trading at a discount (Forward PE: -31.6) compared to its historical average (14.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is in a strong downtrend. Immediate support is located at $2.22, while resistance sits at $2.42.
Market Sentiment: AYTU scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+300.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AYTU is in a strong downtrend. Immediate support is located at $2.22, while resistance sits at $2.42.
Market Sentiment: AYTU scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+300.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.15 -
$2.36
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 300.8% below Wall St target ($9.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.15 -
$2.36
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.22
Resistance Level
$2.42
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-31.60
Wall Street Target
$9.50
(+300.8%)
Revenue Growth (YoY)
-32.7%
Profit Margin
-60.2%
PE vs Historical
-31.6 vs 14.8
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 3:05 PM ET
Data refreshes hourly during market hours. Next update: 4:05 PM
Data refreshes hourly during market hours. Next update: 4:05 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
